About the project

  1. EURO-LEARN
  2. /
  3. About the project

the purpose

The European Increasing Awareness of Nuclear Scintigraphy in Cardiac Amyloidosis (EURO-LEARN) is an initiative that is kindly supported by the European School of Multimodality Imaging & Therapy (ESMIT) as well as the European Association of Nuclear Medicine (EANM), the European Association of Cardiovascular Imaging (EACVI) and also kindly supported by an unrestricted education grant from Pfizer Inc.

EURO-LEARN aims at increasing the awareness of cardiac amyloidosis in Europe by serving as a centralised hub for all related information, a connecting point for patients and professionals to learn more and exchange experiences.

Patients that suffer from cardiac amyloidosis will learn about the bone scanning procedures and medical implications. Have a look at the patients’ zone for more information.

Professionals will get the chance to browse through various guidelines, documentations and cases as well as to collaborate with each other and gain CME accreditation by participating in the eLearning online course on cardiac amyloidosis. Visit the professionals’ part for more details on documentation, collaboration and certification.

These target audiences will directly benefit from the outcomes of this project:

  1. Physicians: cardiologists, nuclear medicine physicians, radiologists (including residents) by learning about whole procedurals in bone scintigraphy in cardiac amyloidosis, particular on acquisition, readings and pitfalls.
  2. Technical medicine physicians/medical physicists to optimise the technical aspects of bone scintigraphy in cardiac amyloidosis.
  3. Patients: This project will contribute to timely diagnosis and subsequent treatment of patients with ATTR cardiomyopathy (ATTR-CM), leading to better prognosis.
get to the professional's zone get to the patient's zone

why is it so important?

The average survival is around 1 year

In many cases we fight time with no luck. This needs to be changed!

What we can do

Supportive care, directed at the underlying cause, dialysis, organ transplantation. That is all we can do so far.

Insufficient knowledge

We know a lot about amyloidosis, but still too little to prevent the disease on time.

We can learn and certify

Thanks to the eLearning course on Cardiac Amyloidosis you can learn much and obtain a professional certificate.

Too late help

In many cases it is too late for treatment. There is very little awareness among potential patients.

But WE CAN TRY to help people earlier!

As a certified professional you will be able to recognise amyloidosis easier and help your patients much faster and more efficiently.

In the past, cardiac amyloidosis was thought to be untreatable and rapidly fatal. However, the field is changing rapidly and the role of bone scintigraphy in cardiac amyloidosis is rising. There are different types of amyloidosis that affect the heart in different ways. Today, many people can expect to survive and experience a good quality of life for several years after diagnosis. It is therefore important to increase the awareness of the disease and treatment options.

In addition to “conventional” bone scintigraphy, EURO-LEARN will share new imaging developments and breakthroughs in cardiac amyloidosis, such as 18F-SodiumFluoride (NaF) PET and the specific targeting amyloid PET compounds 18F-florbetapir and 18F-flobetaben.

Education, eLearning, knowledge flow, certification!

EURO-LEARN is here to educate, create a knowledge base for patients and specialists to exchange knowledge and experiences. We want to provide support in two ways – both for patients and for doctors who can explore the disease, learn to recognise it in advance and increase international relationships between specialists to help and ensure the development of medical knowledge. This is made possible with the certified eLearning course on cardiac amyloidosis!